Equity Research Database

Institutional Investment Pitches

Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.

TimesSquare Capital Management U.S. Mid Cap Growth Strategy's investment thesis on CG Oncology, Inc. ($CGON) — Q1 2026 | Buyside Digest

$CGONNASDAQCG Oncology, Inc.

BULL

TimesSquare Capital Management U.S. Mid Cap Growth Strategy—CGON

Fund Letter

Q1 2026

Published April 20, 2026

$74.62USD

-0.1% vs last month

$68.68Pitched

+8.6% since pitch

Market Cap$6.6B

P/E (TTM)N/A

52-Wk RangeN/A

Div. YieldN/A

CG Oncology Inc. is a late-stage clinical biopharmaceutical company focused on developing therapeutics to treat bladder cancer.

— TimesSquare Capital Management LLC

BSD Research Exclusive

Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($55/mo) and Pro subscribers.

6,000+ Institutional Pitches

Proprietary AI Analysis

100 Letter Unlocks/Cycle

Already a Research or Pro subscriber? Sign In

◆ Keep Reading

Other investors who've written on CG Oncology, Inc.

No other institutional pitches found for this ticker yet.